The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
ApexOnco Front Page
Recent articles
The companies clash over survival curve similarities – and differences.
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
But could toxicity be holding back filing plans?
Syndax scored the first menin approval, but Kura is first with a licensing deal.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
